Abstract 4114
Background
Recombinant super-compound interferon (rSIFN-co) is a new class of interferon derived from altering the spatial structure and configuration of the basic interferon protein. rSIFN-co displayed greater anti-tumor activity in solid tumors compared to interferon α-2b in pre-clinical studies.
Methods
Patients with advanced malignancies were enrolled to determine the safety, tolerability, recommended phase II dose (RP2D), pharmacodynamics (PD) and preliminary anti-tumor activities in a 3 + 3 dose escalation design. rSIFN-co was dosed 3 times a week via subcutaneous injection for 21 days followed by 7 days rest. This was preceded by a lead in phase. PD studies comprised of FDG-PET, pre and post treatment changes in plasma cytokine profile and tumor repressive/ enhancing genes as well as 2’5’-oligoadenylate synthetase levels.
Results
39 treatment refractory patients (pts) were enrolled, 18 (46%) colorectal cancer (CRC), 11 (28%) hepatocellular carcinoma (HCC), 6 (15%) non-small cell lung cancer (NSCLC), 2 (5%) melanoma, 1 (3%) renal cell carcinoma (RCC) and 1 (3%) nasopharyngeal carcinoma (NPC). Gender M/F 25/14, median age 61.0 yrs, and ECOG 0/1/2 - 18/20/1. Patients were dosed at 4 dose levels. No dose limiting toxicities were encountered even at DL4 - 30μg (1.6 × 107IU) 3x/week for 21 days followed by 7 days rest. Most common drug related adverse event (drAE) includes pyrexia (92%), chills (54%), fatigue and anorexia (each 41%) and nausea (26%). Grade 3 drAEs include fatigue (8%), WBC decrease (8%), neutropenia (5%), anorexia and pyrexia and weight loss (3%). No grade 4/5 AE were reported. 2 (5.1%) had PR (2 HCC) maintained at 15.9 and 5.9 mths, 19 (48.7%) had disease control (DCR = PR+SD) of which in 6 (31.5%) DCR was >4 mths (3 HCC, 1 NSCLC and 2 CRC), and median PFS was 2.2 mths. Detailed PD data will be presented for all cohorts.
Conclusions
The RP2D of rSIFN-co was 30ug (1.6 × 107IU) 3x/week for 21days followed by 7 days’ rest. Anti-tumour activity seen in heavily pre-treated advanced solid tumor patients. especially in HCC. Future plans involve combinations with other immunotherapies.
Clinical trial identification
NCT02387307.
Editorial acknowledgement
Legal entity responsible for the study
Sichuan Huiyang Life Science and Technology Corporation.
Funding
Sichuan Huiyang Life Science and Technology Corporation.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4079 - Triggering anti-GBM immune response with EGFR-mediated photoimmunotherapy
Presenter: Gabriela Kramer-marek
Session: Poster Display session 1
Resources:
Abstract
4364 - Upregulation of sFRP3 circulating expression levels correlates survival outcomes in glioblastoma
Presenter: Gema Bruixola
Session: Poster Display session 1
Resources:
Abstract
2327 - Characterization and pre-clinical modeling of genetic aberrations in pediatric gliomas
Presenter: Itai Moshe
Session: Poster Display session 1
Resources:
Abstract
3154 - Preclinical Study of Novel Tetracyclic Small Molecule, CC12, for Brain Cancer
Presenter: Liyun Fann
Session: Poster Display session 1
Resources:
Abstract
5759 - CHLOROBRAIN phase IB trial: The addition of chloroquine, an autophagy inhibitor, to concurrent radiation and temozolomide for newly diagnosed glioblastoma
Presenter: Inge Compter
Session: Poster Display session 1
Resources:
Abstract
1382 - A Phase II Clinical Trial Evaluating the Efficacy and Safety of Apatinib Combined with dose-dense Temozolomide in Recurrent Glioblastoma
Presenter: Yong Wang
Session: Poster Display session 1
Resources:
Abstract
4407 - Phase 0 Trial of Ceritinib in Brain Metastases and Recurrent Glioblastoma
Presenter: Shwetal Mehta
Session: Poster Display session 1
Resources:
Abstract
1469 - Pembrolizumab (Pem) in recurrent high-grade glioma (HGG) patients with mismatch repair deficiency (MMRd): an observational study
Presenter: Mario Caccese
Session: Poster Display session 1
Resources:
Abstract
4217 - Outcome of high-grade gliomas (HGGs) treated into immunotherapeutic early-phase clinical trials (ieCTs): a single-center experience
Presenter: Matteo Simonelli
Session: Poster Display session 1
Resources:
Abstract
5107 - Tolerability of PCV in Low Grade Glioma: a Real World Experience
Presenter: Razia Aslam
Session: Poster Display session 1
Resources:
Abstract